{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:53:12Z","timestamp":1783021992466,"version":"3.54.6"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Axial spondyloarthritis (axSpA) is known to be associated with several extra-skeletal manifestations (ESM), including the inflammatory skin disease psoriasis. It is important to recognize and diagnose psoriasis timely in axSpA in order to provide optimal treatment and outcome for both axSpA and psoriasis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this observational study, all patients from the Dutch Groningen Leeuwarden Axial Spondyloarthritis (GLAS) cohort included before June 2016 were sent a questionnaire with self-screening psoriasis questions including prototypical color pictures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 592 questionnaires sent, 448 (75.7%) were eligible for analysis. Of these 448 respondents, 58 (13%) had a positive self-screening for psoriasis symptoms, currently or in the past. In 28 (48%) of 58 patients, psoriasis diagnosis could be verified by medical records, resulting in a psoriasis prevalence rate of 6.3%. In comparison with patients with a confirmed psoriasis diagnosis, patients reporting psoriasis symptoms without a verified diagnosis mentioned more mild than moderate-severe psoriasis symptoms (25% vs. 3%, <jats:italic>p<\/jats:italic>\u2009=\u20090.02), and their psoriasis lesions were less often located on the torso area (3% vs. 18%, <jats:italic>p<\/jats:italic>\u2009=\u20090.04), the intergluteal cleft (0% vs. 25%, <jats:italic>p<\/jats:italic>\u2009=\u20090.02), and legs (7% vs. 43%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Of the 31 axSpA patients who reported currently active psoriasis, 74% had only mild psoriasis symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Especially mild psoriasis seems often underdiagnosed in patients with axSpA using a patient questionnaire with prototypical pictures of psoriasis lesions. This questionnaire could be beneficial in tracing patients with undiagnosed psoriasis in daily clinical practice. As a next step, further validation of this questionnaire is needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03119-2","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T08:02:40Z","timestamp":1691568160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Psoriasis seems often underdiagnosed in patient with axial spondyloarthritis"],"prefix":"10.1186","volume":"25","author":[{"given":"Angelique","family":"Rondags","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"van Marle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freke R.","family":"Wink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Arends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Spoorenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"issue":"1","key":"3119_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, Van Tubergen A, Castillo-Ortiz JD, et al. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203582.","journal-title":"Ann Rheum Dis."},{"key":"3119_CR2","doi-asserted-by":"publisher","unstructured":"Parisi R, Iskandar Iyk, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https:\/\/doi.org\/10.1136\/bmj.m1590.","DOI":"10.1136\/bmj.m1590"},{"key":"3119_CR3","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","volume":"18","author":"JJ De Winter","year":"2016","unstructured":"De Winter JJ, Van Mens LJ, Van Der Heijde D, et al. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther. 2016;18:196. https:\/\/doi.org\/10.1186\/s13075-016-1093-z.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3119_CR4","first-page":"82","volume":"34","author":"F Roure","year":"2016","unstructured":"Roure F, Elhai M, Burki V, et al. Prevalence and clinical characteristics of psoriasis in spondyloarthritis: a descriptive analysis of 275 patients. Clin Exp Rheumatol. 2016;34(1):82\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"9997","key":"3119_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"Wh Boehncke","year":"2015","unstructured":"Boehncke Wh, Mp S. Psoriasis Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7.","journal-title":"Psoriasis Lancet"},{"issue":"2","key":"3119_CR6","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.rdc.2020.01.009","volume":"46","author":"X Michelena","year":"2020","unstructured":"Michelena X, Poddubnyy D, Marzo-Ortega H. Axial psoriatic arthritis: a distinct clinical entity in search of a definition. Rheum Dis Clin North Am. 2020;46(2):327\u201341. https:\/\/doi.org\/10.1016\/j.rdc.2020.01.009.","journal-title":"Rheum Dis Clin North Am"},{"issue":"6","key":"3119_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","volume":"74","author":"J Callhoff","year":"2015","unstructured":"Callhoff J, Sieper J, Wei\u00df A, et al. Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205322.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3119_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00296-015-3377-z","volume":"36","author":"T Cobo-Ib\u00e1\u00f1ez","year":"2016","unstructured":"Cobo-Ib\u00e1\u00f1ez T, Villaverde V, Seoane-Mato D, et al. Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol Int. 2016;36(2):221\u20139. https:\/\/doi.org\/10.1007\/s00296-015-3377-z.","journal-title":"Rheumatol Int"},{"key":"3119_CR9","doi-asserted-by":"publisher","unstructured":"Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003\u20132004 [published correction appears in J Am Acad Dermatol. 2009;61(3):507]. J Am Acad Dermatol. 2009;60(2):218\u2010224. https:\/\/doi.org\/10.1016\/j.jaad.2008.09.022.","DOI":"10.1016\/j.jaad.2008.09.022"},{"issue":"11","key":"3119_CR10","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1016\/j.mayocp.2020.02.007","volume":"95","author":"MN Magrey","year":"2020","unstructured":"Magrey MN, Danve AS, Ermann J, et al. Recognizing axial spondyloarthritis: a guide for primary care. Mayo Clin Proc. 2020;95(11):2499\u2013508. https:\/\/doi.org\/10.1016\/j.mayocp.2020.02.007.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"3119_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.semarthrit.2018.03.010","volume":"48","author":"A Rondags","year":"2019","unstructured":"Rondags A, Arends S, Wink FR, et al. High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: a possible new extra-articular manifestation. Semin Arthritis Rheum. 2019;48(4):611\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.03.010.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"3119_CR12","doi-asserted-by":"publisher","first-page":"e12589","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. https:\/\/doi.org\/10.1111\/dth.12589.","journal-title":"Dermatol Ther."},{"issue":"1","key":"3119_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/JID.2015.386","volume":"136","author":"EH Modalsli","year":"2016","unstructured":"Modalsli EH, Snekvik I, \u00c5svold BO, et al. Validity of self-reported psoriasis in a general population: the HUNT study. Norway J Invest Dermatol. 2016;136(1):323\u20135. https:\/\/doi.org\/10.1038\/JID.2015.386.","journal-title":"Norway J Invest Dermatol"},{"key":"3119_CR14","unstructured":"Essers I, Ramiro S, Stolwijk C, et al. A. Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS. Clin Exp Rheumatol. 2016;34(2):214\u201321."},{"issue":"2","key":"3119_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3899\/jrheum.210308","volume":"49","author":"R van der Meer","year":"2022","unstructured":"van der Meer R, Arends S, Kruidhof S, et al. Extraskeletal manifestations in axial spondyloarthritis are associated with worse clinical outcomes despite the use of tumor necrosis factor inhibitor therapy. J Rheumatol. 2022;49(2):157\u201364. https:\/\/doi.org\/10.3899\/jrheum.210308.","journal-title":"J Rheumatol"},{"key":"3119_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3899\/jrheum.091461","volume":"85","author":"H El-Gabalawy","year":"2010","unstructured":"El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2\u201310. https:\/\/doi.org\/10.3899\/jrheum.091461.","journal-title":"J Rheumatol Suppl"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03119-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:31:51Z","timestamp":1700353911000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03119-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3119"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03119-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"9 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The GLAS cohort was approved by the local ethics committees of the Medical Center Leeuwarden (MCL) and the University Medical Center Groningen (UMCG).All patients provided written informed consent according to the Declaration of Helsinki, in which they also gave written permission to be approached (non-committal) for SpA-related research.No additional informed consent was needed for this study according to the local ethical committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.R.\u2014Declarations of interest: none.L.v.M.\u2014Declarations of interest: none.B.H.\u2014Declarations of interest: B. Horv\u00e1th reports fees from Janssen-Cilag (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), AbbVie (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), Novartis Pharma (Advisory Boards, Consultations, Investigator Initiative Studies), UCB Pharma (Advisory Boards, Consultations), Leo Pharma (Consultations), Solenne B.V. (Investigator Initiative Studies), Celgene (Consultations, Investigator Initiative Studies), Akari therapeutics (Consultations, Investigator Initiative Studies), Philips (Consultation), Roche (Consultation), Regeneron (Consultation) and Sanofi (Consultation), which fees were paid to the institution.F.R.W.\u2014Declarations of interest: none.S.A.\u2014Declarations of interest: none.A.S.\u2014Declarations of interest: A. Spoorenberg reports fees from AbbVie (Advisory Boards, Educational grants, Consultations), Novartis Pharma (Advisory Boards, Consultations, Investigator Initiative Studies), Pfizer (Advisory Boards, Consultations, Investigator Initiative Studies), UCB Pharma (Advisory Boards, Consultations), which fees were paid to the institution.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}